GeNeuro SA Profile Avatar - Palmy Investing

GeNeuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…

Biotechnology
CH, Plan-les-Ouates [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

GeNeuro SA has no acquisition track records yet.

M&A Deals · History

GeNeuro SA has no acquisition track records yet.

M&A Deals · Within Industry

No current deals within Biotechnology Industry.

M&A Deals · Latest

Act, dont react; Track the most urgent M&A deals across all industries

Details
Owens Corning
Debt
Agg. Maximum Price
$373,155,000.00
Details
?
Equity
Agg. Maximum Price
$n/a
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
?
Equity
Agg. Maximum Price
$2,264,484.00
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
?
Equity
Agg. Maximum Price
$381.73
Details
?
Equity
Agg. Maximum Price
$7,657,428.54
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
?
Equity
Agg. Maximum Price
$19,377,844.50
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00
End of GNRO.PA's Analysis
CIK: - CUSIP: H33418106 ISIN: CH0308403085 LEI: - UEI: -
Secondary Listings
GNRO.PA has no secondary listings inside our databases.